GlassScriptPhysician profile
Julie A Ball
NPI 1093208944
$2,046.09
in general payments reported to CMS, 2019-2025
27 companies · $535 in 2025
The $535 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $331 · 2021: $373 · 2022: $62.22 · 2023: $52.23 · 2024: $64.21 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $651.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $384.61 | 2019-2021 | |
| Pfizer INC. | $337.99 | 2019-2025 | |
| Allergan, INC. | $222.00 | 2019-2021 | |
| Novo Nordisk INC | $200.37 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $131.60 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $119.98 | 2019-2025 | Airsupra |
| Lilly USA, LLC | $70.88 | 2023-2025 | Mounjaro, Jardiance, Kisunla |
| Janssen Pharmaceuticals, INC | $70.05 | 2019 | |
| Glaxosmithkline, LLC. | $67.92 | 2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $63.55 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $39.31 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.17 | 2021-2025 | Xifaxan |
| Seqirus USA INC | $34.93 | 2025 | Fluad, Flucelvax |
| Abbott Laboratories | $30.54 | 2022-2023 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $26.90 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qiagen, LLC | $22.52 | 2021 | |
| Genzyme Corporation | $20.71 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.62 | 2025 | |
| Esperion Therapeutics, INC. | $19.88 | 2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $19.62 | 2021 | |
| Optinose US, INC. | $17.00 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.87 | 2020 | |
| Amgen INC. | $16.85 | 2025 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $14.58 | 2025 | Rexulti |
| Exact Sciences Corporation | $14.34 | 2025 | The Cologuard Plus Collection Kit |
| Abiomed | $13.72 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $13.58 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Ball listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.